Evaluation of suspected malignancies: Difference between revisions

Jump to navigation Jump to search
← Older editNewer edit →
VisualWikitext
Mikael Häggström (talk | contribs)
Administrators, Editors, Image-reviewer, csmoderator, Interface administrators, Administrators, Upload Wizard campaign editors
7,148 edits
Mikael Häggström (talk | contribs)
Administrators, Editors, Image-reviewer, csmoderator, Interface administrators, Administrators, Upload Wizard campaign editors
7,148 edits
Heterogeneity
Line 99: Line 99:
*'''[[Spindle-cell tumors of the midgut]]'''
*'''[[Spindle-cell tumors of the midgut]]'''
*'''[[Soft tissue tumor]]'''</noinclude>
*'''[[Soft tissue tumor]]'''</noinclude>
===Further histopathologic subtyping and grading===
Beyond determining overall malignancy diagnosis (such as adenocarcinoma), probable origin and staging, classification of tumors into a specific histopathologic type or grade is generally of relatively less value. In cases of clearly non-malignant tumors where it is difficult to determine the specific histopathologic type or grade, it is generally acceptable to conclude the evaluation and report it as such, unless the clinician specifically requests otherwise. For potentially malignant or high-risk tumors, typing and grading often still affects the management.


===Undifferentiated tumor===
===Undifferentiated tumor===
Line 107: Line 110:


For example, for a breast biopsy of what appeared to look like a mass, and there is no neoplasia, look mainly for dense fibrosis or other fibrous changes, so that you can report it and thereby explain the finding, rather than merely writing "benign breast tissue".
For example, for a breast biopsy of what appeared to look like a mass, and there is no neoplasia, look mainly for dense fibrosis or other fibrous changes, so that you can report it and thereby explain the finding, rather than merely writing "benign breast tissue".
===Heterogeneity===
After having characterized a suspected malignancy, still screen through it for any significant areas that are different and may need own mentioning, or even change the overall type or grade.


==Additional levels or slices==
==Additional levels or slices==
Line 149: Line 155:
File:Histopathology of typical micropapillary urothelial carcinoma infiltrating the lamina propria - crop.jpg|If unsure whether a case is true lymphovascular invasion or a retraction artifact (imaged), use immunohistochemistry for D2-40 to highlight lymphatic vessels or CD-31 for blood vessels.
File:Histopathology of typical micropapillary urothelial carcinoma infiltrating the lamina propria - crop.jpg|If unsure whether a case is true lymphovascular invasion or a retraction artifact (imaged), use immunohistochemistry for D2-40 to highlight lymphatic vessels or CD-31 for blood vessels.
</gallery>
</gallery>
==Typing and grading==
[[File:Histopathology of pancreatic adenocarcinoma with treatment effect.jpg|thumb|Also note "treatment effect", seen as fibroelastotic tissue, here with scattered remaining tumor cells.]]
[[File:Histopathology of pancreatic adenocarcinoma with treatment effect.jpg|thumb|Also note "treatment effect", seen as fibroelastotic tissue, here with scattered remaining tumor cells.]]
Beyond determining overall malignancy diagnosis (such as adenocarcinoma), probable origin and staging, classification of tumors into a specific histopathologic type or grade is generally of relatively less value. In cases of clearly non-malignant tumors where it is difficult to determine the specific histopathologic type or grade, it is generally acceptable to conclude the evaluation and report it as such, unless the clinician specifically requests otherwise. For potentially malignant or high-risk tumors, typing and grading often still affects the management.


==Reporting==
==Reporting==
Retrieved from "https://patholines.org/Evaluation_of_suspected_malignancies"